PURPOSE OF REVIEW: Due to continuous development of new drugs and better treatment strategies, survival of patients with cystic fibrosis has changed dramatically. Recently, targeted therapy of cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become available. Despite these promising developments, treatment of this complex multiorgan disease constitutes a high and variable amount of other drugs. Complications of pharmacotherapeutic treatment are, therefore, expected to become more prevalent. This gives cause to review drug-related side effects in this new era in cystic fibrosis treatment.RECENT FINDINGS: We will discuss cystic fibrosis-related pharmacotherapies with a focus on indication of treatment, side effects a...
AbstractDrug induced complication are becoming increasingly common in CF. In this review we discuss ...
Cystic fibrosis (CF) is one of the commonest life-limiting genetic disorders in the Caucasian popula...
IntroductionCystic fibrosis (CF) is the most common life-limiting autosomal recessive condition in C...
PURPOSE OF REVIEW: Due to continuous development of new drugs and better treatment strategies, survi...
Purpose of review This review will discuss the challenges of defining a pulmonary exacerbations in c...
This review seeks to re-introduce cystic fibrosis (CF) clinicians to the pharmacology of drug-drug i...
Aims Cystic Fibrosis (CF) is a rare, chronic, progressive, multi-organ disease. It needs life-long,...
The purpose of this review was to identify the history of and advances in cystic fibrosis (CF). New ...
Introduction: Cystic fibrosis (CF) is a lung disease that involves more than 80,000 people globally....
The first regulatory approval for a drug developed specifically for cystic fibrosis (CF) occurred in...
Cystic fibrosis is an autosomal recessive genetic disorder, characterized by mutation in the cystic ...
Background: Cystic fibrosis (CF) is a genetic disease that may result in multiple systemic disorders...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90358/1/phco.25.4.555.61025.pd
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
AbstractDrug induced complication are becoming increasingly common in CF. In this review we discuss ...
Cystic fibrosis (CF) is one of the commonest life-limiting genetic disorders in the Caucasian popula...
IntroductionCystic fibrosis (CF) is the most common life-limiting autosomal recessive condition in C...
PURPOSE OF REVIEW: Due to continuous development of new drugs and better treatment strategies, survi...
Purpose of review This review will discuss the challenges of defining a pulmonary exacerbations in c...
This review seeks to re-introduce cystic fibrosis (CF) clinicians to the pharmacology of drug-drug i...
Aims Cystic Fibrosis (CF) is a rare, chronic, progressive, multi-organ disease. It needs life-long,...
The purpose of this review was to identify the history of and advances in cystic fibrosis (CF). New ...
Introduction: Cystic fibrosis (CF) is a lung disease that involves more than 80,000 people globally....
The first regulatory approval for a drug developed specifically for cystic fibrosis (CF) occurred in...
Cystic fibrosis is an autosomal recessive genetic disorder, characterized by mutation in the cystic ...
Background: Cystic fibrosis (CF) is a genetic disease that may result in multiple systemic disorders...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90358/1/phco.25.4.555.61025.pd
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
AbstractDrug induced complication are becoming increasingly common in CF. In this review we discuss ...
Cystic fibrosis (CF) is one of the commonest life-limiting genetic disorders in the Caucasian popula...
IntroductionCystic fibrosis (CF) is the most common life-limiting autosomal recessive condition in C...